Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-112064 · Präparat HOS-093615
*Effect of atazanavir and ritonavir on the
first dose of glecaprevir and pibrentasvir is
reported.
ANTIPLATELETS
Ticagrelor The mechanism of the interaction is Co-administration of REYATAZ
CYP3A4 inhibition by atazanavir and/or with ticagrelor is not recommended
ritonavir. due to potential increase in the
antiplatelet activity of ticagrelor.
Clopidogrel The mechanism of the interaction is Co-administration with clopidogrel
CYP3A4 inhibition by atazanavir and is not recommended due to
or/ritonavir. potential reduction of the
antiplatelet activity of clopidogrel.
Prasugrel The mechanism of the interaction is No dose adjustment is needed when
CYP3A4 inhibition by atazanavir and prasugrel is co-administered with
or/ritonavir. REYATAZ (with or without
ritonavir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage fd521896b4446bbb2c2aac91bcc7d85d91bd9ff839031dc48ca38ee0153ced32 · Zeichen 7014–8515 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 45
HOS-112167 · Präparat HOS-093615
The mechanism of interaction between
REYATAZ/ritonavir and
sofosbuvir/velpatasvir/voxilaprevir is
inhibition of OATP1B, P-gp, and CYP3A.
Glecaprevir Glecaprevir AUC: ↑553% (↑424% ↑714%) Co-administration of
300 mg/pibrentasvir 120 mg Glecaprevir Cmax: ↑306% (↑215% ↑423%) REYATAZ with
once daily Glecaprevir Cmin: ↑1 330% (↑885% glecaprevir/pibrentasvir is
(atazanavir 300 mg/ritonavir ↑1 970%) contraindicated because of the
100 mg once daily*) potential increase in the risk of
Pibrentasvir AUC: ↑64% (↑48% ↑82%) ALT elevations due to a
Pibrentasvir Cmax: ↑29% (↑15% ↑45%) significant increase in
Pibrentasvir Cmin: ↑129% (↑95% ↑168%) glecaprevir and pibrentasvir
plasma concentrations
*Effect of atazanavir and ritonavir on the (see section 4.3)
first dose of glecaprevir and pibrentasvir is
reported.
ANTIPLATELETS
Ticagrelor The mechanism of the interaction is Co-administration of
CYP3A4 inhibition by atazanavir and/or REYATAZ with ticagrelor is
ritonavir. not recommended due to
potential increase in the
antiplatelet activity of
ticagrelor.
Clopidogrel The mechanism of the interaction is Co-administration with
CYP3A4 inhibition by atazanavir and clopidogrel is not
or/ritonavir. recommended due to potential
reduction of the antiplatelet
activity of clopidogrel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) clopidogrel (HOS-087927) velpatasvir (HOS-108929) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage edfcf541a931e4b83eae4873165bcf47e213e3efb25690eb982fd8615b53d1c1 · Zeichen 5708–8232 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87–88
HOS-116581 · Präparat HOS-094447
87
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 27a092d7005e5ab0411f0babdff280e728008e3766038685e07864d1fc35a1d1 · Zeichen 2308–2745 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 15–16
HOS-116363 · Präparat HOS-094447
15
ANTIBIOTIC
Clarithromycin clarithromycin AUC ↑ 57% Caution should be exercised when
500 mg twice daily
clarithromycin Cmin ↑ 174% clarithromycin is combined with
clarithromycin Cmax ↑ 26% boosted PREZISTA.
#
darunavir AUC ↓ 13%
#
darunavir Cmin ↑ 1% For patients with renal impairment
# the Summary of Product
darunavir Cmax ↓ 17%
Characteristics for clarithromycin
14-OH-clarithromycin concentrations
should be consulted for the
were not detectable when combined with
recommended dose.
PREZISTA/ritonavir.
(↑ clarithromycin from CYP3A inhibition
and possible P-gp inhibition)
ANTICOAGULANT/PLATELET AGGREGATION INHIBITOR
Apixaban Not studied. Co-administration of The use of boosted PREZISTA
Rivaroxaban boosted PREZISTA with these with a direct oral anticoagulant
anticoagulants may increase (DOAC) that is metabolised by
concentrations of the anticoagulant. CYP3A4 and transported by P-gp
(CYP3A and/or P-gp inhibition) is not recommended as this may
lead to an increased bleeding risk.
Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir:
Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose
dose: reduction of the DOAC should be
dabigatran AUC ↑ 72% considered when a DOAC
dabigatran Cmax ↑ 64% transported by P-gp but not
metabolised by CYP3A4,
darunavir/ritonavir 800/100 mg once including dabigatran etexilate and
daily: edoxaban, is co-administered with
dabigatran AUC ↑ 18% PREZISTA/rtv.
dabigatran Cmax ↑ 22%
Darunavir/cobicistat:
darunavir/cobicistat 800/150 mg single Clinical monitoring and dose
dose: reduction is required when a
dabigatran AUC ↑ 164% DOAC transported by P-gp but not
dabigatran Cmax ↑ 164% metabolised by CYP3A4,
including dabigatran etexilate and
darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with
daily: PREZISTA/cobi.
dabigatran AUC ↑ 88%
dabigatran Cmax ↑ 99%
Ticagrelor Concomitant administration of
Based on theoretical considerations,
boosted PREZISTA with ticagrelor
co-administration of boosted PREZISTA
is contraindicated (see section 4.3).
with ticagrelor may increase
concentrations of ticagrelor (CYP3A
and/or P-glycoprotein inhibition).
Clopidogrel Co-administration of clopidogrel
Not studied. Co-administration of
with boosted PREZISTA is not
clopidogrel with boosted PREZISTA is
recommended. Use of other
expected to decrease clopidogrel active
antiplatelets not affected by CYP
metabolite plasma concentration, which
inhibition or induction (e.g.
may reduce the antiplatelet activity of
prasugrel) is recommended.
clopidogrel.
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio
boosted PREZISTA. (INR) be monitored when warfarin
is combined with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) cobicistat (HOS-088111) dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) clopidogrel (HOS-087927) clarithromycin (HOS-084517) edoxaban (HOS-086234) apixaban (HOS-112091) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage c517feec8afcc30d3aa41f1410083f5273e19d3aef8a7a29cc68426909e25762 · Zeichen 29322–34850 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-116519 · Präparat HOS-094447
Ticagrelor Based on theoretical considerations, Concomitant administration of
co-administration of boosted PREZISTA boosted PREZISTA with ticagrelor
with ticagrelor may increase is contraindicated (see section 4.3).
concentrations of ticagrelor (CYP3A
and/or P-glycoprotein inhibition).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8290bcc59b368895425f3172774c10f263bde323c43d3b902de7292b6a287851 · Zeichen 25549–25968 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 97–98
HOS-116609 · Präparat HOS-094447
97
Dabigatran etexilate dabigatran etexilate (150 mg): Darunavir/ritonavir:
Edoxaban darunavir/ritonavir 800/100 mg single Clinical monitoring and/or dose
dose: reduction of the DOAC should be
dabigatran AUC ↑ 72% considered when a DOAC
dabigatran Cmax ↑ 64% transported by P-gp but not
metabolised by CYP3A4,
darunavir/ritonavir 800/100 mg once including dabigatran etexilate and
daily: edoxaban, is co-administered with
dabigatran AUC ↑ 18% PREZISTA/rtv.
dabigatran Cmax ↑ 22%
Darunavir/cobicistat:
darunavir/cobicistat 800/150 mg single Clinical monitoring and dose
dose: reduction is required when a
dabigatran AUC ↑ 164% DOAC transported by P-gp but not
dabigatran Cmax ↑ 164% metabolised by CYP3A4,
including dabigatran etexilate and
darunavir/cobicistat 800/150 mg once edoxaban, is co-administered with
daily: PREZISTA/cobi.
dabigatran AUC ↑ 88%
dabigatran Cmax ↑ 99%
Ticagrelor Based on theoretical considerations, Concomitant administration of
co-administration of boosted PREZISTA boosted PREZISTA with ticagrelor
with ticagrelor may increase is contraindicated (see section 4.3).
concentrations of ticagrelor (CYP3A
and/or P-glycoprotein inhibition).
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted PREZISTA is with boosted PREZISTA is not
expected to decrease clopidogrel active recommended. Use of other
metabolite plasma concentration, which antiplatelets not affected by CYP
may reduce the antiplatelet activity of inhibition or induction (e.g.
clopidogrel prasugrel) is recommended.
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio
boosted PREZISTA. (INR) be monitored when warfarin
is combined with boosted
PREZISTA.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with
Phenytoin are expected to decrease plasma low dose ritonavir should not be
concentrations of darunavir and its used in combination with these
pharmacoenhancer. medicines.
(induction of CYP450 enzymes)
The use of these medicines with
PREZISTA/cobicistat is
contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) phenobarbital (HOS-085617) cobicistat (HOS-088111) dabigatran (HOS-112096) clopidogrel (HOS-087927) edoxaban (HOS-086234) prasugrel (HOS-112066) ritonavir (HOS-084521) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 39d7135aa5b8b1dfa56535d5e896900efac27586a70d7bbd090683d83951a637 · Zeichen 31232–35170 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-118638 · Präparat HOS-094855
There was no meaningful interaction observed when verapamil was given
2 hours after dabigatran etexilate (increase of Cmax by about 1.1-fold and AUC by
about 1.2-fold). This is explained by completed dabigatran absorption after
2 hours.
Amiodarone When dabigatran etexilate was co-administered with a single oral dose of 600 mg
amiodarone, the extent and rate of absorption of amiodarone and its active
metabolite DEA were essentially unchanged. The dabigatran AUC and Cmax were
increased by about 1.6-fold and 1.5-fold, respectively. In view of the long
half-life of amiodarone the potential for an interaction may exist for weeks after
discontinuation of amiodarone (see sections 4.2 and 4.4).
Quinidine Quinidine was given as 200 mg dose every 2nd hour up to a total dose of
1 000 mg. Dabigatran etexilate was given twice daily over 3 consecutive days, on
the 3rd day either with or without quinidine. Dabigatran AUCτ,ss and Cmax,ss were
increased on average by 1.53-fold and 1.56-fold, respectively with concomitant
quinidine (see sections 4.2 and 4.4).
Clarithromycin When clarithromycin (500 mg twice daily) was administered together with
dabigatran etexilate in healthy volunteers, increase of AUC by about 1.19-fold
and Cmax by about 1.15-fold was observed.
Ticagrelor When a single dose of 75 mg dabigatran etexilate was coadministered
simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC
and Cmax were increased by 1.73-fold and 1.95-fold, respectively. After multiple
doses of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold
and 1.46-fold for Cmax and AUC, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) quinidine (HOS-085593) dabigatran (HOS-112096) clarithromycin (HOS-084517) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage f116df601c50f4f32f2fd36d8bc3a9439cdd0a0e7e55d2f7ca9f4bc9db279c31 · Zeichen 3385–5363 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-118639 · Präparat HOS-094855
Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg
dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss
by 1.49-fold and 1.65-fold, respectively, compared with dabigatran etexilate
given alone. When a loading dose of 180 mg ticagrelor was given 2 hours after
110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUCτ,ss
and Cmax,ss was reduced to 1.27-fold and 1.23-fold, respectively, compared with
dabigatran etexilate given alone. This staggered intake is the recommended
administration for start of ticagrelor with a loading dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage df838b72b33ea00260c132801d8349fab4dfff70c30a801486844f300e7008dc · Zeichen 5383–6121 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12–13
HOS-118640 · Präparat HOS-094855
12
Concomitant administration of 90 mg ticagrelor b.i.d. (maintenance dose) with
110 mg dabigatran etexilate increased the adjusted dabigatran AUCτ,ss and Cmax,ss
1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given
alone.
Posaconazole Posaconazole also inhibits P-gp to some extent but has not been clinically
studied. Caution should be exercised when dabigatran etexilate is co-
administered with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 6e97d07200fcbf44595bf112e7395a533d9747cd31fb49d4057fa0941e139ebf · Zeichen 6172–6746 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-118650 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8130–8723 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 45
HOS-118714 · Präparat HOS-094855
There was no meaningful interaction observed when verapamil was given
2 hours after dabigatran etexilate (increase of Cmax by about 1.1-fold and AUC by
about 1.2-fold). This is explained by completed dabigatran absorption after
2 hours.
Amiodarone When dabigatran etexilate was co-administered with a single oral dose of 600 mg
amiodarone, the extent and rate of absorption of amiodarone and its active
metabolite DEA were essentially unchanged. The dabigatran AUC and Cmax were
increased by about 1.6-fold and 1.5-fold, respectively. In view of the long
half-life of amiodarone the potential for an interaction may exist for weeks after
discontinuation of amiodarone (see sections 4.2 and 4.4).
Quinidine Quinidine was given as 200 mg dose every 2nd hour up to a total dose of
1 000 mg. Dabigatran etexilate was given twice daily over 3 consecutive days, on
the 3rd day either with or without quinidine. Dabigatran AUCτ,ss and Cmax,ss were
increased on average by 1.53-fold and 1.56-fold, respectively with concomitant
quinidine (see sections 4.2 and 4.4).
Clarithromycin When clarithromycin (500 mg twice daily) was administered together with
dabigatran etexilate in healthy volunteers, increase of AUC by about 1.19-fold
and Cmax by about 1.15-fold was observed.
Ticagrelor When a single dose of 75 mg dabigatran etexilate was coadministered
simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC
and Cmax were increased by 1.73-fold and 1.95-fold, respectively. After multiple
doses of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold
and 1.46-fold for Cmax and AUC, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) quinidine (HOS-085593) dabigatran (HOS-112096) clarithromycin (HOS-084517) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage f116df601c50f4f32f2fd36d8bc3a9439cdd0a0e7e55d2f7ca9f4bc9db279c31 · Zeichen 3379–5357 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 45
HOS-118715 · Präparat HOS-094855
Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg
dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss
by 1.49-fold and 1.65-fold, respectively, compared with dabigatran etexilate
given alone. When a loading dose of 180 mg ticagrelor was given 2 hours after
110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUCτ,ss
and Cmax,ss was reduced to 1.27-fold and 1.23-fold, respectively, compared with
dabigatran etexilate given alone. This staggered intake is the recommended
administration for start of ticagrelor with a loading dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage df838b72b33ea00260c132801d8349fab4dfff70c30a801486844f300e7008dc · Zeichen 5377–6115 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 45
HOS-118716 · Präparat HOS-094855
Concomitant administration of 90 mg ticagrelor b.i.d. (maintenance dose) with
110 mg dabigatran etexilate increased the adjusted dabigatran AUCτ,ss and Cmax,ss
1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given
alone.
Posaconazole Posaconazole also inhibits P-gp to some extent but has not been clinically
studied. Caution should be exercised when dabigatran etexilate is co-
administered with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage f3ee454c5eae8d79c09bcc2f81baced624c7d2e4ae2be1e80b4546ee4b86fba6 · Zeichen 6135–6666 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 110 mg hard capsules · Abschnitt 4.5 · PDF-Seite 46
HOS-118725 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8103–8696 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 85
HOS-118802 · Präparat HOS-094855
There was no meaningful interaction observed when verapamil was given 2 hours
after dabigatran etexilate (increase of Cmax by about 1.1-fold and AUC by about
1.2-fold). This is explained by completed dabigatran absorption after 2 hours.
Amiodarone When dabigatran etexilate was co-administered with a single oral dose of 600 mg
amiodarone, the extent and rate of absorption of amiodarone and its active
metabolite DEA were essentially unchanged. The dabigatran AUC and Cmax were
increased by about 1.6-fold and 1.5-fold, respectively. In view of the long
half-life of amiodarone the potential for an interaction may exist for weeks after
discontinuation of amiodarone (see sections 4.2 and 4.4).
Quinidine Quinidine was given as 200 mg dose every 2nd hour up to a total dose of
1 000 mg. Dabigatran etexilate was given twice daily over 3 consecutive days, on
the 3rd day either with or without quinidine. Dabigatran AUCτ,ss and Cmax,ss were
increased on average by 1.53-fold and 1.56-fold, respectively with concomitant
quinidine (see sections 4.2 and 4.4).
Clarithromycin When clarithromycin (500 mg twice daily) was administered together with
dabigatran etexilate in healthy volunteers, increase of AUC by about 1.19-fold
and Cmax by about 1.15-fold was observed.
Ticagrelor When a single dose of 75 mg dabigatran etexilate was coadministered
simultaneously with a loading dose of 180 mg ticagrelor, the dabigatran AUC and
Cmax were increased by 1.73-fold and 1.95-fold, respectively. After multiple doses
of ticagrelor 90 mg b.i.d. the increase of dabigatran exposure is 1.56-fold and
1.46-fold for Cmax and AUC, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) quinidine (HOS-085593) dabigatran (HOS-112096) clarithromycin (HOS-084517) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage bdfa628f609b22924acbe4ce6fae304d53f4f2b512b0f2820f2a05513d3391a4 · Zeichen 3393–5374 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 85
HOS-118803 · Präparat HOS-094855
Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg
dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss
by 1.49-fold and 1.65-fold, respectively, compared with dabigatran etexilate
given alone. When a loading dose of 180 mg ticagrelor was given 2 hours after
110 mg dabigatran etexilate (in steady state), the increase of dabigatran AUCτ,ss
and Cmax,ss was reduced to 1.27-fold and 1.23-fold, respectively, compared with
dabigatran etexilate given alone. This staggered intake is the recommended
administration for start of ticagrelor with a loading dose.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 8dc01bb29791b001c0e21de8dfbd7ed2382bea5307f4d4b2f75d72811383111b · Zeichen 5395–6140 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 85
HOS-118804 · Präparat HOS-094855
Concomitant administration of 90 mg ticagrelor b.i.d. (maintenance dose) with
110 mg dabigatran etexilate increased the adjusted dabigatran AUCτ,ss and Cmax,ss
1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given
alone.
Posaconazole Posaconazole also inhibits P-gp to some extent but has not been clinically
studied. Caution should be exercised when dabigatran etexilate is co-
administered with posaconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) dabigatran (HOS-112096) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage 3cee6202e0ec882d3e007199f731ea8e06be796533596be39d5b85a78085ca0c · Zeichen 6161–6698 im Abschnitt
Wechselwirkungen · Pradaxa
Pradaxa 150 mg hard capsules · Abschnitt 4.5 · PDF-Seite 86
HOS-118814 · Präparat HOS-094855
There is no or only limited experience with the following treatments which may increase the risk of
bleeding when used concomitantly with dabigatran etexilate: anticoagulants such as unfractionated
heparin (UFH), low molecular weight heparins (LMWH), and heparin derivatives (fondaparinux,
desirudin), thrombolytic medicinal products, and vitamin K antagonists, rivaroxaban or other oral
anticoagulants (see section 4.3), and antiplatelet aggregation medicinal products such as GPIIb/IIIa
receptor antagonists, ticlopidine, prasugrel, ticagrelor, dextran, and sulfinpyrazone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) sulfinpyrazone (HOS-089177) fondaparinux (HOS-110096) dextran (HOS-118654) vitamin K (HOS-091176) heparin (HOS-086930) rivaroxaban (HOS-086236) prasugrel (HOS-112066) desirudin (HOS-118651) ticlopidine (HOS-087946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-24T16:05:00Z · SHA-256 6fdebd4ffab4d65c0f88f2d9fedf86e816358c723b5b8edac8e90f1c47487499 · Passage a2f6a9478f57630a4c855e173bebe15e2bee9f3bdbecaa93d3fe6350a29c6ded · Zeichen 8119–8712 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.